Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, rupatadine (Rupafin®) 1 mg/ml oral solution cannot be endorsed for use within NHS Wales for the treatment of symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) in children aged 6 to 11 years. |
||
|
||
Medicine details |
||
| Medicine name | rupatadine (Rupafin®) | |
| Formulation | 1 mg/ml oral solution | |
| Reference number | 1755 | |
| Indication | For the treatment of symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) in children aged 6 to 11 years. |
|
| Company | GlaxoSmithKline | |
| BNF chapter | Respiratory system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 07/08/2012 | |
| Date of issue | 13/08/2012 | |